N-(3-hydroxy-[2]naphthyl)-acetamide | 67347-17-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: N-(3-hydroxy-[2]naphthyl)-acetamide
• 英文别名: 3-Acetamino-naphthol-(2)；N-(3-Hydroxy-[2]naphthyl)-acetamid；N-(3-hydroxynaphthalen-2-yl)acetamide
• CAS: 67347-17-5
• 化学式: C₁₂H₁₁NO₂
• 分子量: 201.225
• InChiKey: GVLLPLLOSZNYMI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(3-hydroxy-[2]naphthyl)-acetamide 在 硫酸 、 sodium nitrite 作用下， 生成 3-acetylamino-[1,2]naphthoquinone-1-oxime
  参考文献：
  名称：

  叔丁基3-乙酰氨基1,2-萘醌

  摘要：

  DOI：

  10.1002/hlca.19370200196
• 作为产物：
  描述：

  乙酰氯 、 3-氨基-2-萘酚 在 sodium carbonate 、 盐酸 作用下， 以 水 、 丙酮 为溶剂， 以78%的产率得到N-(3-hydroxy-[2]naphthyl)-acetamide
  参考文献：
  名称：

  [EN] QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION
  [FR] COMPOSÉ DE QUINOLONE ET AGENT PHARMACEUTIQUE

  摘要：

  本发明提供了一种喹诺酮化合物，该化合物能够抑制帕金森病的慢性进展或保护多巴胺神经元免受疾病病因的影响，从而抑制神经功能障碍的进展，以便在延长给予L-多巴的时间的同时改善神经元功能；本发明的喹诺酮化合物由公式(1)表示：其中：R1代表氢等；R2代表氢等；R3代表取代或未取代的苯基等；R4代表卤素等；R5代表氢等；R6代表氢等；R7代表氢等。

  公开号：

  WO2010064735A1

文献信息

• [EN] QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION<br/>[FR] COMPOSÉ DE QUINOLONE ET AGENT PHARMACEUTIQUE
  申请人：OTSUKA PHARMA CO LTD

  公开号：WO2010064735A1

  公开（公告）日：2010-06-10

  The present invention provides a quinolone compound that inhibits the chronic progression of Parkinson's disease or protects dopamine neurons from disease etiology, thereby suppressing the progression of neurological dysfunction, so as to prolong the period of time until L-dopa is administered while also improving neuronal function; the quinolone compound of the invention is represented by Formula (1): wherein: R1 represents hydrogen or the like; R2 represents hydrogen or the like; R3 represents substituted or unsubstituted phenyl or the like; R4 represents halogen or the like; R5 represents hydrogen or the like; R6 represents hydrogen or the like; and R7 represents hydrogen or the like.

  本发明提供了一种喹诺酮化合物，该化合物能够抑制帕金森病的慢性进展或保护多巴胺神经元免受疾病病因的影响，从而抑制神经功能障碍的进展，以便在延长给予L-多巴的时间的同时改善神经元功能；本发明的喹诺酮化合物由公式(1)表示：其中：R1代表氢等；R2代表氢等；R3代表取代或未取代的苯基等；R4代表卤素等；R5代表氢等；R6代表氢等；R7代表氢等。
• [EN] PIGMENT COMPOSITION, INK FOR INKJET RECORDING, COLORING COMPOSITION FOR COLOR FILTER, AND COLOR FILTER<br/>[FR] COMPOSITION DE PIGMENT, ENCRE POUR L'IMPRESSION PAR JET D'ENCRE, COMPOSITION COLORANTE POUR FILTRE COLORÉ ET FILTRE COLORÉ
  申请人：FUJIFILM CORP

  公开号：WO2011087148A1

  公开（公告）日：2011-07-21

  A pigment composition containing an azo pigment represented by the following general formula (1) and a pigment derivative having a hydrophilic group: wherein G represents a hydrogen atom, an aliphatic group, an aryl group, a heterocyclic group, an acyl group, an aliphatic oxycarbonyl group, a carbamoyl group, an aliphatic sulfonyl group, or an arylsulfonyl group, R1 represents an amino group, an aliphatic oxy group, an aliphatic group, an aryl group, or a heterocyclic group, R2 represents a substituent, A represents an aromatic 5- or 6-membered heterocyclic group, m represents an integer of from 0 to 5, and n represents an integer of from 1 to 4, with the general formula (1) not containing any ionic hydrophilic group.

  一种含有以下一般式（1）所代表的偶氮颜料和具有亲水基团的颜料衍生物的颜料组合物：其中G代表氢原子、脂肪族基团、芳基、杂环基团、酰基、脂肪族氧羰基团、氨基羰基团、脂肪族磺酰基团或芳基磺酰基团，R1代表氨基、脂肪族氧基、脂肪族基团、芳基或杂环基团，R2代表取代基，A代表芳香5-或6-成员杂环基团，m表示0至5的整数，n表示1至4的整数，一般式（1）不含任何离子性亲水基团。
• QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION
  申请人：Otsubo Kenji

  公开号：US20110269705A1

  公开（公告）日：2011-11-03

  The present invention provides a quinolone compound that inhibits the chronic progression of Parkinson's disease or protects dopamine neurons from disease etiology, thereby suppressing the progression of neurological dysfunction, so as to prolong the period of time until L-dopa is administered while also improving neuronal function; the quinolone compound of the invention is represented by Formula (1): wherein: R 1 represents hydrogen or the like; R 2 represents hydrogen or the like; R 3 represents substituted or unsubstituted phenyl or the like; R 4 represents halogen or the like; R 5 represents hydrogen or the like; R 6 represents hydrogen or the like; and R 7 represents hydrogen or the like.

  本发明提供了一种喹诺酮化合物，用于抑制帕金森病的慢性进展或保护多巴胺神经元免受疾病病因的影响，从而抑制神经功能障碍的进展，延长L-多巴胺治疗之前的时间，并改善神经元功能；本发明的喹诺酮化合物由式（1）表示：其中：R1代表氢或类似物；R2代表氢或类似物；R3代表取代或未取代的苯基或类似物；R4代表卤素或类似物；R5代表氢或类似物；R6代表氢或类似物；R7代表氢或类似物。
• Organic Compounds
  申请人：Barnes David

  公开号：US20100197744A1

  公开（公告）日：2010-08-05

  Novel compounds that are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inhibitors of other enzymes characterized with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds of the present invention may be employed for prevention and/or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels, conditions that accompany type-2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated. In addition, the compounds of the present invention may be employed to treat and/or prevent cancer, osteoporosis, neurodegenerative and infectious diseases, and diseases involving inflammation and the immune system.

  新型化合物可作为蛋白酪氨酸磷酸酶（PTPase）的抑制剂，因此可用于治疗由PTPase活性介导的疾病。本发明的化合物也可作为其他酶的抑制剂，这些酶具有磷酸酪氨酸结合区域，如SH2结构域。因此，本发明的化合物可用于预防和/或治疗与肥胖相关的胰岛素抵抗、葡萄糖不耐受、糖尿病、高血压和大、小血管缺血性疾病，伴随2型糖尿病的疾病，包括高脂血症、高甘油三酯血症、动脉粥样硬化、血管再狭窄、肠易激综合征、胰腺炎、脂肪细胞肿瘤和脂肪肉瘤、失调脂质代谢以及其他表现为胰岛素抵抗的疾病。此外，本发明的化合物可用于治疗和/或预防癌症、骨质疏松症、神经退行性和感染性疾病以及涉及炎症和免疫系统的疾病。
• Quinolone compound and pharmaceutical composition
  申请人：Otsuka Pharmaceutical Co., Ltd.

  公开号：US08304546B2

  公开（公告）日：2012-11-06

  The present invention provides a quinolone compound that inhibits the chronic progression of Parkinson's disease or protects dopamine neurons from disease etiology, thereby suppressing the progression of neurological dysfunction, so as to prolong the period of time until L-dopa is administered while also improving neuronal function; the quinolone compound of the invention is represented by Formula (1): wherein: R1 represents hydrogen or the like; R2 represents hydrogen or the like; R3 represents substituted or unsubstituted phenyl or the like; R4 represents halogen or the like; R5 represents hydrogen or the like; R6 represents hydrogen or the like; and R7 represents hydrogen or the like.

  本发明提供了一种喹诺酮化合物，该化合物能够抑制帕金森病的慢性进展或保护多巴胺神经元免受疾病病因的影响，从而抑制神经功能障碍的进展，延长L-多巴胺治疗之前的时间，同时改善神经元功能；本发明的喹诺酮化合物由式（1）表示：其中：R1代表氢或类似物；R2代表氢或类似物；R3代表取代或未取代的苯基或类似物；R4代表卤素或类似物；R5代表氢或类似物；R6代表氢或类似物；R7代表氢或类似物。